ReviewFrontiers in immunology2026
Research advances on NLRP3 inflammasomes in organ transplantation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nucleotide metabolic reprogramming: a "double-edged sword" in obesity-related inflammation-from metabolic adaptation to pathological imbalance.Journal of physiology and biochemistry · 2026Review
- Pathophysiological mechanisms of cell death affecting graft survival in liver transplantation.World journal of transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ transplantation is a life-saving therapy for end-organ failure; however, long-term outcomes are limited by complications such as ischemia-reperfusion injury (IRI), allograft rejection, and infection. The NLRP3 inflammasome, a key innate immune signaling platform, plays a central role in driving inflammation in these settings. Its activation follows a two-signal paradigm and contributes critically to tissue damage during IRI, bridges innate and adaptive immunity in acute and chronic rejection, and exerts context-dependent roles, either protective or detrimental, during infection. Although targeting NLRP3 through genetic, pharmacological, or cellular approaches shows therapeutic promise in preclinical studies, clinical translation remains challenging. Future efforts should focus on refining these strategies and elucidating its interplay within broader immune networks to improve transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.